Featuring slide presentations and related discussion from Dr Nikhil I Khushalani, Dr Soo J Park, Dr Vishal Anil Patel and Dr Evan Wuthrick, including the following topics:

• Introduction (0:00)
• Current Management of Localized, Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) (9:55)
• Case: A man in his early 70s with cSCC who previously underwent surgery and adjuvant therapy (32:39)
• Case: A man in his early 60s with cSCC who receives cemiplimab (54:45)
• Incorporation of Radiation Therapy into the Multidisciplinary Management of cSCC and Basal Cell Carcinoma (BCC) (1:04:24)
• Case: A man in his early 70s with cSCC who receives radiation therapy after a surgeon expresses concern about the risks of surgery (1:22:15)
• Case: A man in his late 80s with cSCC who is not a candidate for surgery (1:24:09)
• Evidence-Based Treatment Strategies for Patients with BCC (1:26:00)
• Case: A man in his mid sixties with BCC who receives sonidegib (1:36:49)
• Case: A man in his late 70s with BCC who receives vismodegib (1:38:32)
• Dermatologic Care for Patients with cSCC and BCC (1:45:09)

CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

• Case: A man in his early 40s with chronic immune thrombocytopenia (ITP) receives romiplostim with rituximab — Bhavana (Tina) Bhatnagar, DO (0:00)
• Case: A woman in her early 80s with metastatic adenocarcinoma of the lung responds to carboplatin/pemetrexed/pembrolizumab but after 14 months of maintenance pembrolizumab presents with ITP — Susmitha Apuri, MD (6:48)
• Case: A man in his late 70s with a 30-year history of chronic ITP who received corticosteroids and rituximab now receives avatrombopag — Sunil Gandhi, MD (12:06)
• Case: A woman in her early 80s with multiple comorbidities and a long history of ITP presents with confusion and fluid retention due to exacerbated congestive heart failure and receives fostamatinib — Dr Bhatnagar (19:26)

CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25)
• Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54)
• Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15)

CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics:

• Introduction: Use of On-Body Glucose Monitoring Devices (0:00)
• Overview of Breast Cancer and Diabetes (9:39)
• PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28)
• Case Presentations — Part 1 (26:02)
• Current Data with Alpelisib, Capivasertib and Inavolisib (43:51)
• Prevention and Management of Hyperglycemia (1:02:17)
• Case Presentations — Part 2 (1:10:24)

CME information and select publications

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics:

• Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00)
• Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33)
• Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07)

CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

• Neoadjuvant immunotherapy for localized rectal cancer (0:00)
• Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14)
• Determining a treatment strategy for resectable colon cancer (12:35)

CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

• Introduction (0:00)
• Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27)
• Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30)
• Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56)
• Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47)

CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

• Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00)
• Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13)
• Clinical applications for zanidatamab in GE cancer (13:58)

CME information and select publications